• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

    2/12/24 12:03:27 PM ET
    $AXNX
    Medical/Dental Instruments
    Health Care
    Get the next $AXNX alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 AXONICS INC COMMON STOCK Cusip #05465P101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05465P101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,159,697 Item 6: 0 Item 7: 1,179,132 Item 8: 0 Item 9: 1,179,132 Item 11: 2.322% Item 12: HC Cusip #05465P101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,179,132 Item 8: 0 Item 9: 1,179,132 Item 11: 2.322% Item 12: IN Item 1(a). Name of Issuer: AXONICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 26 TECHNOLOGY DRIVE IRVINE, CA 92618 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 05465P101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 1,179,132 (b) Percent of Class: 2.322% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,179,132 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AXONICS INC. No one other person's interest in the COMMON STOCK of AXONICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of AXONICS INC at January 31, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $AXNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXNX

    DatePrice TargetRatingAnalyst
    1/9/2024Outperform → Peer Perform
    Wolfe Research
    7/19/2023$69.00Outperform
    Robert W. Baird
    7/13/2023$70.00Overweight
    KeyBanc Capital Markets
    5/23/2023$75.00Buy
    CL King
    4/14/2023$75.00Buy
    Mizuho
    3/24/2023$71.00Hold → Buy
    Needham
    10/21/2022$85.00Outperform
    RBC Capital Mkts
    10/12/2022$75.00Hold
    Jefferies
    More analyst ratings

    $AXNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific Closes Acquisition of Axonics, Inc.

      MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti

      11/15/24 8:43:00 AM ET
      $AXNX
      $BSX
      Medical/Dental Instruments
      Health Care
    • Axonics Reports Third Quarter 2024 Financial Results

      Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str

      11/7/24 4:01:00 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

      Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20

      9/26/24 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:20 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:14 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Director Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)

      4 - Axonics, Inc. (0001603756) (Issuer)

      11/15/24 9:00:06 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

      Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

      7/25/24 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

      BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

      12/27/23 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics Announces CFO Retirement and Appoints Successor

      Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. "On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years," said Raymond W. Cohen, chief executive officer. "Dan has played an instrumental role in Axonics' success and the significant value that

      8/21/23 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/13/24 4:59:03 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/12/24 12:03:27 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/9/24 8:35:54 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

      MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.

      1/31/24 6:30:00 AM ET
      $AXNX
      $BSX
      Medical/Dental Instruments
      Health Care
    • Axonics Reports Third Quarter 2023 Financial Results

      Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. "Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based on the s

      10/30/23 4:01:00 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Axonics to Report Third Quarter 2023 Financial Results on October 30

      Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 3Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 3Q23 webcast. A replay of the webcast will be archived in t

      10/2/23 6:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Axonics Modulation downgraded by Wolfe Research

      Wolfe Research downgraded Axonics Modulation from Outperform to Peer Perform

      1/9/24 6:49:41 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Axonics Modulation with a new price target

      Robert W. Baird initiated coverage of Axonics Modulation with a rating of Outperform and set a new price target of $69.00

      7/19/23 7:13:39 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • KeyBanc Capital Markets initiated coverage on Axonics Modulation with a new price target

      KeyBanc Capital Markets initiated coverage of Axonics Modulation with a rating of Overweight and set a new price target of $70.00

      7/13/23 7:29:51 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care

    $AXNX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Axonics Inc.

      15-12G - Axonics, Inc. (0001603756) (Filer)

      11/25/24 9:05:44 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Axonics Inc.

      EFFECT - Axonics, Inc. (0001603756) (Filer)

      11/21/24 12:15:05 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Axonics Inc.

      25-NSE - Axonics, Inc. (0001603756) (Subject)

      11/15/24 2:23:54 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care